Headlines about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.807604092212 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of GlycoMimetics (NASDAQ:GLYC) traded down 3.34% during mid-day trading on Friday, hitting $13.60. The stock had a trading volume of 313,422 shares. The stock’s 50-day moving average is $11.43 and its 200 day moving average is $9.19. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $16.94. The company’s market cap is $445.03 million.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. On average, equities research analysts forecast that GlycoMimetics will post ($1.22) earnings per share for the current fiscal year.

Several research analysts have commented on the company. ValuEngine upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. SunTrust Banks, Inc. set a $21.00 target price on GlycoMimetics and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $17.00 target price (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. GlycoMimetics has an average rating of “Hold” and an average target price of $14.20.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact GlycoMimetics (GLYC) Share Price” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/24/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-glycomimetics-glyc-share-price.html.

In other news, SVP Helen M. Thackray sold 2,000 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $13.00, for a total value of $26,000.00. Following the completion of the transaction, the senior vice president now owns 150,615 shares of the company’s stock, valued at $1,957,995. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 43.80% of the company’s stock.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.